Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718815 | 0.90 | MEN1 (0.53) | FAAHMGLLPOLBMEN1KMT2A | |
| SCHEMBL5963786 | 0.84 | MGLL (0.61) | FAAHMGLLPOLBMEN1KMT2A | |
| SCHEMBL29211489 | 0.84 | FAAH (0.40) | FAAHMGLLPOLBMEN1KMT2A | |
| SCHEMBL508459 | 0.84 | FAAH (0.40) | FAAHMGLLPOLBMEN1KMT2A | |
| SCHEMBL371216 | 0.82 | MGLL (0.70) | FAAHMGLLPOLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28995394 | 0.82 | MGLL (0.59) | FAAHMGLLPOLBMEN1KMT2A | |
| SCHEMBL8863095 | 0.82 | POLB (0.43) | FAAHMGLLPOLBMEN1KMT2A | |
| SCHEMBL9018615 | 0.82 | FAAH (0.42) | FAAHMGLLPOLBMEN1KMT2A | |
| SCHEMBL40386 | 0.80 | MGLL (0.68) | FAAHMGLLPOLBMEN1KMT2A | |
| SCHEMBL7198335 | 0.80 | MGLL (0.68) | FAAHMGLLPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5688312-A | INKS WITH COLORS AND IMIDES OR BISIMIDES, FOR ACOUSTIC INK PRINTER AND DROP EJECTOR | XEROX CORPORATION (US) | 1997-11-18 | — | — | US | claimed |
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-22 | — | — | US | disclosed |
| US-20230338564-A1 | NEODEGRADER CONJUGATES | ORUM THERAPEUTICS, INC. (FR) | 2023-10-26 | — | — | US | disclosed |
| EP-4230735-A1 | COMPOSITIONS AND METHODS COMPRISING SERINE PROTEASE VARIANTS | Danisco US Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-115975009-A | Enhanced fluorescent antibody, preparation method and application thereof | 广州睿贝医学科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115916812-A | GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2023-04-04 | — | — | CN | disclosed |
| EP-4126920-A2 | GIF RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126921-A2 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335395-A | QD administration of GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2022-11-11 | — | — | CN | disclosed |
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20060172201-A1 | Non-aqueous electrolyte and lithium secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| EP-1357628-A1 | NONAQUEOUS ELECTROLYTIC LIQUIDS AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
| US-5688312-A | INKS WITH COLORS AND IMIDES OR BISIMIDES, FOR ACOUSTIC INK PRINTER AND DROP EJECTOR | XEROX CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0252242-B1 | PROCESS FOR THE MANUFACTURE OF C1 TO C6 N-ALKYL PYRROLIDONES FROM SUCCINIC-ACID ANHYDRIDE OR A C1 TO C6 N-ALKYL SUCCINIMIDE | HÜLS AKTIENGESELLSCHAFT (DE) | 1990-11-28 | — | — | EP | disclosed |
| US-4780547-A | USING NICKEL HYDROGENATION CATALYST | HUELS AKTIENGESELLSCHAFT (DE) | 1988-10-25 | — | — | US | disclosed |
| US-4490487-A | SO3 /Imide adducts, process for their preparation and their use as sulphonating agents | BAYER AKTIENGESELLSCHAFT (DE) | 1984-12-25 | — | — | US | disclosed |
| EP-0112541-A1 | SO3 imide adducts, process for their preparation and their uses as sulfonating agents | BAYER AG (DE) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | FAAH 379/4885MGLL 2702/4885POLB 1684/4885 |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | FAAH 1691/4885MGLL 1320/4885POLB 4224/4885 |
| US-20230338564-A1 | NEODEGRADER CONJUGATES | CD44, FOLR1, CD47 | FAAH 4686/4885MGLL 4525/4885POLB 259/4885 |
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | AVPR1B, PRLHR, HRH4 | FAAH 1784/4885MGLL 4821/4885POLB 1885/4885 |
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | GIPR, GLP1R, GPR119 | FAAH 2807/4885MGLL 2318/4885POLB 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.